​

Taysha Gene Therapies Ownership | Who Owns Taysha Gene Therapies?

OverviewForecastRevenueFinancialsChartTranscripts

Taysha Gene Therapies Ownership Summary

Taysha Gene Therapies is owned by 41.02% institutional investors, 11.14% insiders, and 47.84% retail investors. Rtw investments, lp is the largest institutional shareholder, holding 8.17% of TSHA shares. Fidelity Growth Compy Commingled Pl O is the top mutual fund, with 3.16% of its assets in Taysha Gene Therapies shares.

TSHA Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockTaysha Gene Therapies41.02%11.14%47.84%
SectorHealthcare Stocks 232.01%10.74%-142.75%
IndustryBiotech Stocks 381.47%10.55%-292.02%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Rtw investments, lp24.35M8.17%$79.64M
Ra capital management23.56M7.90%$77.03M
Avoro capital advisors21.70M7.28%$70.96M
Blackrock funding, inc. /de18.64M5.28%$102.54M
Morgan stanley18.08M5.12%$99.43M
Blackrock11.74M5.08%$26.30M
Fmr14.59M4.90%$47.72M
Goldman sachs group13.69M3.88%$75.31M
Vanguard group13.27M3.76%$72.97M
Siren11.01M3.70%$36.02M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Tybourne capital management (hk)3.70M39.11%$12.10M
Octagon capital advisors lp9.07M4.49%$29.65M
B group1.80M4.33%$5.89M
Ally bridge group (ny)1.90M3.78%$6.21M
Great point partners1.50M2.02%$4.91M
Acuta capital partners454.83K1.54%$1.49M
Siren11.01M1.41%$36.02M
Quantum private wealth819.72K1.32%$4.51M
Rtw investments, lp24.35M0.98%$79.64M
Ra capital management23.56M0.95%$77.03M

Top Buyers

HolderShares% AssetsChange
Blackrock11.74M0.00%9.15M
Affinity asset advisors3.00M0.85%2.80M
Vestal point capital, lp5.50M0.81%2.50M
Blackrock funding, inc. /de18.64M0.00%2.28M
State street7.24M0.00%2.10M

Top Sellers

HolderShares% AssetsChange
Octagon capital advisors lp9.07M4.49%-3.52M
Vr adviser---3.23M
Suvretta capital management---3.22M
Bioimpact capital---2.95M
Toronto dominion bank1.92M0.01%-2.80M

New Positions

HolderShares% AssetsChangeValue
Ally bridge group (ny)1.90M3.78%1.90M$6.21M
Norges bank1.84M0.00%1.84M$10.11M
Abrdn1.02M0.01%1.02M$5.62M
Eam investors823.76K0.50%823.76K$4.53M
Rice hall james & associates578.12K0.10%578.12K$1.89M

Sold Out

HolderChange
Quadrant capital group-2.00
National bank of canada /fi/-48.00
Riggs asset managment-198.00
Coldstream capital management-207.00
Morton brown family wealth-260.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 2025141-10.76%144,935,051-45.23%410.52%934.49%27-20.59%
Sep 30, 20251537.75%264,590,86716.57%881.53%86-1.15%346.25%
Jun 30, 202514816.54%257,619,95754.48%862.25%9045.16%3310.00%
Mar 31, 202512-90.63%63,845,739-61.79%250.66%7-90.41%1-96.00%
Dec 31, 20241265.00%167,074,7106.47%621.82%72-4.00%2556.25%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Fidelity Growth Compy Commingled Pl O6.48M3.16%-
RTW Biotech Opportunities Ord7.80M2.85%7.80M
Polar Capital Biotech S Inc7.50M2.74%2.75M
Vanguard Total Stock Mkt Idx Inv6.85M2.50%-
Vanguard US Total Market Shares ETF4.46M2.17%-
State Street® SPDR® S&P® Biotech ETF5.91M2.16%-31.82K
Fidelity Growth Compy Commingled Pl S5.42M1.98%11.02K
iShares Russell 2000 ETF5.34M1.95%5.34M
Fidelity Growth Company Fund4.18M1.52%-23.54K
Xtrackers MSCI World Swap ETF 1C2.47M1.20%-

Recent Insider Transactions

DateNameRoleActivityValue
Feb 04, 2026Alam Kamran CHIEF FINANCIAL OFFICERSell$7.48K
Jan 26, 2026Nagendran Sukumar President and Head of R&DSell$124.09K
Jan 23, 2026Nagendran Sukumar President and Head of R&DSell$423.38K
Jan 23, 2026Nolan Sean P. Chief Executive OfficerSell$649.75K
Jan 26, 2026Nolan Sean P. Chief Executive OfficerSell$190.45K

Insider Transactions Trends

DateBuySell
2026 Q1-8
2025 Q4-2
2025 Q3-3
2025 Q21-
2025 Q1--

TSHA Ownership FAQ

Who Owns Taysha Gene Therapies?

Taysha Gene Therapies shareholders are primarily institutional investors at 41.02%, followed by 11.14% insiders and 47.84% retail investors. The average institutional ownership in Taysha Gene Therapies's industry, Biotech Stocks , is 381.47%, which Taysha Gene Therapies falls below.

Who owns the most shares of Taysha Gene Therapies?

Taysha Gene Therapies’s largest shareholders are Rtw investments, lp (24.35M shares, 8.17%), Ra capital management (23.56M shares, 7.90%), and Avoro capital advisors (21.7M shares, 7.28%). Together, they hold 23.36% of Taysha Gene Therapies’s total shares outstanding.

Does Blackrock own Taysha Gene Therapies?

Yes, BlackRock owns 5.08% of Taysha Gene Therapies, totaling 11.74M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 26.3M$. In the last quarter, BlackRock increased its holdings by 9.15M shares, a 352.10% change.

Who is Taysha Gene Therapies’s biggest shareholder by percentage of total assets invested?

Tybourne capital management (hk) is Taysha Gene Therapies’s biggest shareholder by percentage of total assets invested, with 39.11% of its assets in 3.7M Taysha Gene Therapies shares, valued at 12.1M$.

Who is the top mutual fund holder of Taysha Gene Therapies shares?

Fidelity Growth Compy Commingled Pl O is the top mutual fund holder of Taysha Gene Therapies shares, with 3.16% of its total shares outstanding invested in 6.48M Taysha Gene Therapies shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools